INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

LEFT ATRIAL APPANDAGE CLOSURE

Çağatay Tunca

Ankara Etlik City Hospital, Department of Cardiology, Ankara, Türkiye

Tunca Ç. Left Atrial Appandage Closure. In: Tanık VO, Özlek B, editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.491-510.

ABSTRACT

Left atrial appendage closure is an approach developed to reduce the risk of stroke in patients with atrial fibrillation. Due to the risk of bleeding associated with the use of oral anticoagulants, percutaneous closure methods are increasingly preferred. While devices such as WATCHMAN, Amulet and LAmbre provide effective closure of the left atrial appendage, the procedure is usually performed under transseptal puncture and imaging guidance. After closure, complications such as peridevice leaks, device-related thrombus and pericardial effusion should be monitored. Current data support appendix closure as a safe and effective option in high-risk patients, but further research is needed on long-term outcomes and optimal antithrombotic treatment strategies.

Keywords: Atrial fibrillation; Stroke

Referanslar

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561-4. [Crossref]  [PubMed]
  2. Noseworthy PA, Kaufman ES, Chen LY, et al. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation. 2019;140(25):e944-e963. [Crossref]  [PubMed]  [PMC]
  3. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons [published correction appears in Circulation. 2019 Aug 6;140(6):e285. [Crossref]  [PubMed]
  4. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42: 373-498. [Crossref]  [PubMed]
  5. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al. Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016;9:e003333. [Crossref]  [PubMed]
  6. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-9. [Crossref]  [PubMed]
  7. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. [Crossref]  [PubMed]
  8. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015;38:555-61. [Crossref]  [PubMed]  [PMC]
  9. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9. [Crossref]  [PubMed]
  10. Hsu JC, Maddox TM, Kennedy KF, et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55-62. [Crossref]  [PubMed]
  11. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):e003074. [Crossref]  [PubMed]  [PMC]
  12. Holmes DR Jr, Schwartz RS, Latus GG, Van Tassel RA. A History of Left Atrial Appendage Occlusion. Interv Cardiol Clin. 2018;7:143-50. [Crossref]  [PubMed]
  13. Ono S, Kubo K, Maruo T, Kar S, Kadota K. Left atrial appendage size in patients with atrial fibrillation in Japan and the United States. Heart Vessels. 2021;36:277-84. [Crossref]  [PubMed]
  14. Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left atrial appendage: anatomy, function, and noninvasive evaluation. J Am Coll Cardiol Img. 2014;7:1251-65. [Crossref]  [PubMed]
  15. Biase LD, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial f ibrillation? Results from a multicenter study. J Am Coll Cardiol 2012;60:531-8. [Crossref]  [PubMed]
  16. Mumin A, Olabu B, Kaisha W, Saidi H, Ogeng'o J. Morphology of the left atrial ap pendage: prevalence and gender difference in a Kenyan population. J Morphol Sci. 2018;35:48-53. [Crossref]
  17. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999;82:547-55. [Crossref]  [PubMed]  [PMC]
  18. Cox JL, Boineau JP, Schuessler RB, Kater KM, Lappas DG. Five-year experience with the maze procedure for atrial fibrillation. Ann Thorac Surg 1993;56:814-23. [Crossref]  [PubMed]
  19. Majunke N, Sandri M, Adams V, Daehnert I, Mangner N, Schuler G, et al. Atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial ap pendage with the watchman device. J Invasive Cardiol 2015;27:448-52. [PubMed]
  20. Cox JL. Mechanical closure of the left atrial appendage: is it time to be more aggres sive? J Thorac Cardiovasc Surg 2013;146:1018-27. [Crossref]  [PubMed]
  21. Badhwar V, Rankin JS, Damiano RJ Jr, et al. The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. Ann Thorac Surg. 2017;103(1):329-341. [Crossref]  [PubMed]
  22. Ibrahim AM, Tandan N, Koester C, Abdelkarim J, Maini R, Labrdi M, et al. Meta analysis evaluating outcomes of surgical left atrial appendage occlusion during car diac surgery. Am J Cardiol. 2019;124:1218-25. [Crossref]  [PubMed]
  23. Hanke T. Surgical management of the left atrial appendage: a must or a myth? Eur J Cardiothorac Surg. 2018;53:i33-8. [Crossref]  [PubMed]
  24. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150(2):288-293. [Crossref]  [PubMed]
  25. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med. 2021;384:2081-91. [Crossref]  [PubMed]
  26. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial f ibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (percutaneous left atrial appendage transcatheter occlusion) study. JACC Cardiovasc Interv. 2009;2:594-600. [Crossref]  [PubMed]
  27. Bayard YL, Omran H, Neuzil P, et al. PLAATO (percutaneous left atrial appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention. 2010;6:220-6. [Crossref]  [PubMed]
  28. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49:1490-5. [Crossref]  [PubMed]
  29. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-42. [Crossref]  [PubMed]
  30. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12. [Crossref]  [PubMed]
  31. Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PRE VAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964-75. [Crossref]  [PubMed]
  32. Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75:3122-35. [Crossref]  [PubMed]
  33. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation. 2011;123:417-24. [Crossref]  [PubMed]
  34. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient level meta-analysis. J Am Coll Cardiol. 2015;65:2614-23. [Crossref]  [PubMed]
  35. Reddy VY, Gibson DN, Kar S, et al. Post-approval U. S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2017;69:253-61. [Crossref]  [PubMed]
  36. Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appen dage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143:1754-62. [Crossref]  [PubMed]
  37. Paitazoglou C, Meincke F, Bergmann MW, et al. The ALSTER-FLX registry: 3-month outcomes after left atrial appendage occlusion using a next-generation device, a matchedpair analysis to EWOLUTION. Heart Rhythm. 2022;19:917-26. [Crossref]  [PubMed]
  38. Price MJ, Friedman DJ, Du C, et al. Comparative safety of transcatheter laao with the first-generation watchman and next-generation watchman FLX devices. JACC Cardiovasc Interv. 2022;15:2115-23. [Crossref]  [PubMed]
  39. Kapadia SR. Real-world outcomes with WATCH MAN FLX: early results from SURPASS. 2022. [Link]
  40. Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLAT ZER Amulet device: periprocedural and early clini cal/echocardiographic data from a global prospective observational study. EuroIntervention. 2017;13:867-76. [Crossref]  [PubMed]
  41. Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (amulet IDE): a randomized, controlled trial. Circulation. 2021;144:1543-52. [Crossref]  [PubMed]  [PMC]
  42. Huang H, Liu Y, Xu Y, et al. Percutaneous left atrial appendage closure with the LAmbre device for stroke prevention in atrial fibrillation: a prospec tive, multicenter clinical study. JACC Cardiovasc Interv. 2017;10:2188-94. [Crossref]  [PubMed]
  43. FreemanJV, Varosy P, Price MJ, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Car diol. 2020;75:1503-18. [Crossref]  [PubMed]  [PMC]
  44. Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstro¨m-Lundqvist C. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. Europace. 2015;17:642-6. [Crossref]  [PubMed]
  45. Manning WJ, Weintraub RM, Waksmonski CA, Haering JM, Rooney PS, Maslow AD, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995;123:817-22. [Crossref]  [PubMed]
  46. Hong SJ, Kim JY, Kim JB, et al. Multidetector computed tomography may be an adequate screening test to reduce periprocedural stroke in atrial fibrillation ablation: a multicenter propensity-matched analysis. Heart Rhythm. 2014;11(5):763-770. [Crossref]  [PubMed]
  47. Pracon R, Bangalore S, Dzielinska Z, Konka M, Kepka C, Kruk M, et al. Device Thrombosis After Percutaneous Left Atrial Appendage Occlusion Is Related to Patient and Procedural Characteristics but Not to Duration of Postimplantation Dual Antiplatelet Therapy. Circ Cardiovasc Interv. 2018;11:e005997. [Crossref]  [PubMed]
  48. Aytemir K, Canpolat U, Yorgun H, Evranos B, Kaya EB, Şahiner ML, et al. Usefulness of 'figure-of-eight' suture to achieve haemostasis after removal of 15-French calibre femoral venous sheath in patients undergoing cryoablation. Europace. 2016;18:1545-50. [Crossref]  [PubMed]
  49. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609-78. [Crossref]  [PubMed]
  50. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral antico agulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol. 2013;61:2551-6. [Crossref]  [PubMed]
  51. Akashi S, Oguri M, Ikeno E, et al. Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF ran domized clinical trial. JAMA Netw Open. 2022;5:e2228500. [Crossref]  [PubMed]  [PMC]
  52. Della Rocca DG, Magnocavallo M, Di Biase L, et al. Half-dose direct oral anticoagulation versus stan dard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc Interv. 2021;14:2353-64. [Crossref]  [PubMed]
  53. Yerasi C, Lazkani M, Kolluru P, et al. An updated systematic review and meta-analysis of early out comes after left atrial appendage occlusion. J Interv Cardiol. 2018;31:197-206. 50. [Crossref]  [PubMed]
  54. Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without con traindication to oral anticoagulation: 1-year follow up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14:1302-8. [Crossref]  [PubMed]
  55. Aminian A, Lalmand J, Tzikas A, Budts W, Benit E, Kefer J. Embolization of left atrial appendage clo sure devices: a systematic review of cases reported with the watchman device and the amplatzer car diac plug. Catheter Cardiovasc Interv. 2015;86:128-35. [Crossref]  [PubMed]
  56. Dukkipati SR, Holmes DR Jr, Doshi SK, et al. Impact of peridevice leak on 5-year outcomes after left atrial appendage closure. J Am Coll Cardiol. 2022;80:469-83. [Crossref]  [PubMed]
  57. Lempereur M, Aminian A, Saw J. Rebuttal with regards to ''device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet.'' Catheter Cardiovasc Interv. 2018;92:E216-E217. [Crossref]  [PubMed]
  58. Fauchier L, Cinaud A, Brigadeau F, et al. Device related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol. 2018;71:1528-36. [Crossref]  [PubMed]
  59. Asmarats L, Cruz-Gonza'lez I, Nombela-Franco L, et al. Recurrence of device-related thrombus after percutaneous left atrial appendage closure. Circu lation. 2019;140:1441-3. [Crossref]  [PubMed]
  60. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in col laboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. [Crossref]  [PubMed]